TOI Quote, Financials, Valuation and Earnings

Encompass Health has a net margin of -18.76% compared to The Oncology Institute's net margin of 10.41%. The Oncology Institute's return on equity of -340.01% beat Encompass Health's return on equity of 18.4%.

The Oncology Institute has a consensus price target of $7.00, signalling upside risk potential of 124.36%. On the other hand Encompass Health has an analysts' consensus of $131.27 which suggests that it could grow by 9.83%. Given that The Oncology Institute has higher upside potential than Encompass Health, analysts believe The Oncology Institute is more attractive than Encompass Health.

The Oncology Institute has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Encompass Health has a beta of 0.930, suggesting its less volatile than the S&P 500 by 7.02%.

The Oncology Institute has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Encompass Health offers a yield of 0.55% to investors and pays a quarterly dividend of $0.17 per share. The Oncology Institute pays -- of its earnings as a dividend. Encompass Health pays out 13.78% of its earnings as a dividend. Encompass Health's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

The Oncology Institute quarterly revenues are $104.4M, which are smaller than Encompass Health quarterly revenues of $1.5B. The Oncology Institute's net income of -$19.6M is lower than Encompass Health's net income of $151.5M. Notably, The Oncology Institute's price-to-earnings ratio is -- while Encompass Health's PE ratio is 24.69x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for The Oncology Institute is 0.59x versus 2.21x for Encompass Health. Usually stocks with elevated PS ratios are considered overvalued.

Pediatrix Medical Group has a net margin of -18.76% compared to The Oncology Institute's net margin of 4.52%. The Oncology Institute's return on equity of -340.01% beat Pediatrix Medical Group's return on equity of -10.7%.

The Oncology Institute has a consensus price target of $7.00, signalling upside risk potential of 124.36%. On the other hand Pediatrix Medical Group has an analysts' consensus of $17.14 which suggests that it could grow by 24.95%. Given that The Oncology Institute has higher upside potential than Pediatrix Medical Group, analysts believe The Oncology Institute is more attractive than Pediatrix Medical Group.

The Oncology Institute has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Pediatrix Medical Group has a beta of 1.263, suggesting its more volatile than the S&P 500 by 26.315%.

The Oncology Institute has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pediatrix Medical Group offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. The Oncology Institute pays -- of its earnings as a dividend. Pediatrix Medical Group pays out -- of its earnings as a dividend.

The Oncology Institute quarterly revenues are $104.4M, which are smaller than Pediatrix Medical Group quarterly revenues of $458.4M. The Oncology Institute's net income of -$19.6M is lower than Pediatrix Medical Group's net income of $20.7M. Notably, The Oncology Institute's price-to-earnings ratio is -- while Pediatrix Medical Group's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for The Oncology Institute is 0.59x versus 0.58x for Pediatrix Medical Group. Usually stocks with elevated PS ratios are considered overvalued.

US Physical Therapy has a net margin of -18.76% compared to The Oncology Institute's net margin of 6.97%. The Oncology Institute's return on equity of -340.01% beat US Physical Therapy's return on equity of 4.62%.

The Oncology Institute has a consensus price target of $7.00, signalling upside risk potential of 124.36%. On the other hand US Physical Therapy has an analysts' consensus of $106.00 which suggests that it could grow by 40.55%. Given that The Oncology Institute has higher upside potential than US Physical Therapy, analysts believe The Oncology Institute is more attractive than US Physical Therapy.

The Oncology Institute has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison US Physical Therapy has a beta of 1.438, suggesting its more volatile than the S&P 500 by 43.783%.

The Oncology Institute has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. US Physical Therapy offers a yield of 2.36% to investors and pays a quarterly dividend of $0.45 per share. The Oncology Institute pays -- of its earnings as a dividend. US Physical Therapy pays out 100.3% of its earnings as a dividend.

The Oncology Institute quarterly revenues are $104.4M, which are smaller than US Physical Therapy quarterly revenues of $183.8M. The Oncology Institute's net income of -$19.6M is lower than US Physical Therapy's net income of $12.8M. Notably, The Oncology Institute's price-to-earnings ratio is -- while US Physical Therapy's PE ratio is 34.60x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for The Oncology Institute is 0.59x versus 1.63x for US Physical Therapy. Usually stocks with elevated PS ratios are considered overvalued.